The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO GI 2025 | ctDNA as a biomarker for monitoring treatment response in pancreatic cancer
Alexander Spira, MD, PhD, Virginia Cancer Specialist, Fairfax, VA, comments on the value of cell-free DNA (ctDNA) as a biomarker in pancreatic cancer, highlighting its potential for monitoring patients and predicting response to treatment before undergoing CT scans. Dr Spira notes that while response rates may be lower than in other tumor types, the presence of ctDNA in stable disease patients suggests that tumors are still responding to treatment, and this may ultimately translate to improved progression-free and overall survival outcomes. This interview took place at the ASCO GI Cancers Symposium 2025 in San Francisco, CA This interview took place at the ASCO GI Cancers Symposium 2025 in San Francisco, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
